Trials / Completed
CompletedNCT01392729
An Observational Study of Avastin (Bevacizumab) and Interferon Alpha 2a in Patients With Metastatic Renal Cell Cancer (VERA)
An Open Label, Prospective, Observational, Local, Non-interventional Study of BeVacizumab (Avastin) and IntErpherone (IFN) Alpha 2a in Patients With Metastatic and Locally Advanced Renal Cell CAncer (VERA Study)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 40 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This prospective observational study will evaluate the efficacy and safety of Avastin (bevacizumab) in combination with interferon alpha 2a in patients with previously untreated metastatic renal cell cancer. Data will be collected from each patient for up to 4 years.
Conditions
Timeline
- Start date
- 2010-09-01
- Primary completion
- 2015-06-01
- Completion
- 2015-06-01
- First posted
- 2011-07-12
- Last updated
- 2016-11-02
Locations
1 site across 1 country: Romania
Source: ClinicalTrials.gov record NCT01392729. Inclusion in this directory is not an endorsement.